Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Califf’s Top Priorities For New Year: Misinformation And Evidence Generation

Feb 02 2024

• By Brenda Sandburg

Robert Califf at CERSI — FDA Commissioner Robert Califf notes his prioirities for 2024 • Source: screenshot

Related Content

Califf Kicks Off Commissionership With Pledge To Counter Misinformation

Feb 18 2022

US FDA Mulls Granting Regulated Industry Flexibility To Respond To Misinformation

Jan 11 2023

Califf Plans US FDA, NIH Collaboration On Postmarket Evidence Generation

May 25 2023

Califf’s New Spin On US FDA Staffing: Attrition Rate Is Too Low

Jun 22 2023

US FDA Commissioner Califf Takes On Misinformation, Starting With ‘Rumor Control’

Aug 05 2022

Combatting Misinformation: FDA’s Califf On Use Of Facts, Opinion And Emotion

Jan 25 2024

AAM Calls For Congress And FDA To End Shortages By Easing Up On Generics Quality, Pricing

Jul 04 2023

New Year’s Predictions From FDA Leadership Past And Present: GLP-1s, Mental Health, Big Data

Jan 09 2024

Additional Topics

United States Leadership FDA Regulation Post Market Regulation & Studies Market Access Generic Drugs Pricing Debate BioPharmaceutical

More from Agency Leadership

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window